Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy
NCT02423707
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
110
Enrollment
OTHER
Sponsor class
Conditions
Allergic Rhinitis
Interventions
DRUG:
ALK Alutard Birch and/or 5-grasses
DRUG:
ALK Diluent
Sponsor
Karolinska Institutet
Collaborators
[object Object]
[object Object]